Antibody–drug conjugates (ADCs) are a promising cancer treatment modality that enables the selective delivery of highly cytotoxic payloads to tumours. However, realizing the full potential of this ...

AE and MMAE are highly stable molecules. There were no signs of compound degradation after 16 d in buffered saline at 37 °C. Furthermore, there was no evidence for drug metabolism or decomposition in ...

Probody drug conjugates, immune-stimulating antibody conjugates, engineered toxin bodies, radioligand conjugates, and so on comprise the new wave of molecules in clinical development, seeking to ...

The past decade in oncology has been marked by the rise of immunotherapy, which leverages the immune system to attack tumors. For many solid tumors, immune checkpoint inhibitors have supplanted ...